The U.S Food and Drug Administration’s (FDA) recent approval of Gadopiclenol injection, a gadolinium-based contrast agent (GBCA) for magnetic resonance imaging (MRI), paves the way for a new marketing paradigm that is designed to ensure the broadest possible access to patients and their healthcare professionals in need of imaging agents.

HistoSonics, the developer of a non-invasive, novel sonic beam therapy, has raised $85 million in a financing led by Johnson & Johnson Innovation, to support its anticipated commercial launch, additional clinical trials, and to expand application development of Edison, the company’s novel histotripsy therapy platform, throughout the body.

FLEXcon Company, an innovator in adhesive coating and lami-nating, has initiated the commercialization of FLEXcon OMNI-WAVE Signal Receptive Media Components, a revolutionary biosensing technology that eliminates the need for hydrogel in medical diagnostic and therapeutic wearable devices.

It is widely held that “time is money” to highlight the important role efficiency can play in a business when it comes to making a profit or creating value. Similarly, we can all concede that “time is life” in the healthcare industry as doctors and nurses in the hospital race against time every day to […]